[Targeted therapy of urological tumours. Experimental field or established therapeutic approach?]

M W Kramer; S Krege; I Peters; A S Merseburger; M A Kuczyk

doi:10.1007/s00120-010-2397-2

[Targeted therapy of urological tumours. Experimental field or established therapeutic approach?]

Urologe A. 2010 Oct;49(10):1260-5. doi: 10.1007/s00120-010-2397-2.

[Article in German]

Authors

M W Kramer¹, S Krege, I Peters, A S Merseburger, M A Kuczyk

Affiliation

¹ Klinik für Urologie und Urologische Onkologie, Medizinische Hochschule Hannover, Hannover.

PMID: 20848076
DOI: 10.1007/s00120-010-2397-2

Abstract

Unlike conventional systemic chemotherapies, the aim of targeted therapeutic approaches is not to address general mechanisms involved in cellular replication. In contrast, they aim at such regulatory pathways that have been identified to be involved in the progression of human malignant disease. Whereas the application of targeted therapeutic modalities is well established for the treatment of metastatic renal cell cancer, only very few data on their clinical efficacy during the treatment of other urological tumours such as prostate and bladder cancer are currently available. The aim of this paper is to reflect on the current status regarding the relevance of targeted therapeutic approaches during the treatment of urological cancers of different origin.

Publication types

Review

MeSH terms

Antibodies, Monoclonal / administration & dosage
Antineoplastic Agents / administration & dosage*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Carcinoma, Renal Cell / drug therapy
Carcinoma, Renal Cell / mortality
Carcinoma, Transitional Cell / drug therapy
Carcinoma, Transitional Cell / mortality
Disease Progression
Drug Delivery Systems*
Drug Resistance, Neoplasm
Drugs, Investigational / administration & dosage*
Female
Humans
Kidney Neoplasms / drug therapy
Kidney Neoplasms / mortality
Male
Prognosis
Prostatic Neoplasms / drug therapy
Prostatic Neoplasms / mortality
Protein-Tyrosine Kinases / antagonists & inhibitors
Randomized Controlled Trials as Topic
Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors
TOR Serine-Threonine Kinases / antagonists & inhibitors
Testicular Neoplasms / drug therapy
Testicular Neoplasms / mortality
Urinary Bladder Neoplasms / drug therapy
Urinary Bladder Neoplasms / mortality
Urologic Neoplasms / drug therapy*
Urologic Neoplasms / mortality

Substances

Antibodies, Monoclonal
Antineoplastic Agents
Drugs, Investigational
MTOR protein, human
Protein-Tyrosine Kinases
Receptors, Vascular Endothelial Growth Factor
TOR Serine-Threonine Kinases